[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

PL3156420T3 - Humanizowane przeciwciała przeciw liv-1 i ich stosowanie w leczeniu raka - Google Patents

Humanizowane przeciwciała przeciw liv-1 i ich stosowanie w leczeniu raka

Info

Publication number
PL3156420T3
PL3156420T3 PL16200557T PL16200557T PL3156420T3 PL 3156420 T3 PL3156420 T3 PL 3156420T3 PL 16200557 T PL16200557 T PL 16200557T PL 16200557 T PL16200557 T PL 16200557T PL 3156420 T3 PL3156420 T3 PL 3156420T3
Authority
PL
Poland
Prior art keywords
liv
same
humanized antibodies
treat cancer
cancer
Prior art date
Application number
PL16200557T
Other languages
English (en)
Inventor
Maria Leia Smith
Django Sussman
William Arthur
Albina Nesterova
Original Assignee
Seattle Genetics, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Seattle Genetics, Inc. filed Critical Seattle Genetics, Inc.
Publication of PL3156420T3 publication Critical patent/PL3156420T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A61K47/6865—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from skin, nerves or brain cancer cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3015—Breast
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3053—Skin, nerves, brain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
    • C07K16/464—Igs containing CDR-residues from one specie grafted between FR-residues from another
    • C07K16/465—Igs containing CDR-residues from one specie grafted between FR-residues from another with additional modified FR-residues
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Reproductive Health (AREA)
  • Pregnancy & Childbirth (AREA)
  • Gynecology & Obstetrics (AREA)
  • Neurosurgery (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
PL16200557T 2010-12-06 2011-12-06 Humanizowane przeciwciała przeciw liv-1 i ich stosowanie w leczeniu raka PL3156420T3 (pl)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US42029110P 2010-12-06 2010-12-06
US201161446990P 2011-02-25 2011-02-25
EP11847198.6A EP2648752B1 (en) 2010-12-06 2011-12-06 Humanized antibodies to liv-1 and use of same to treat cancer
PCT/US2011/063612 WO2012078688A2 (en) 2010-12-06 2011-12-06 Humanized antibodies to liv-1 and use of same to treat cancer
EP16200557.3A EP3156420B1 (en) 2010-12-06 2011-12-06 Humanized antibodies to liv-1 and use of same to treat cancer

Publications (1)

Publication Number Publication Date
PL3156420T3 true PL3156420T3 (pl) 2019-08-30

Family

ID=46207694

Family Applications (3)

Application Number Title Priority Date Filing Date
PL16200557T PL3156420T3 (pl) 2010-12-06 2011-12-06 Humanizowane przeciwciała przeciw liv-1 i ich stosowanie w leczeniu raka
PL18204152T PL3461847T3 (pl) 2010-12-06 2011-12-06 Przeciwciała humanizowane przeciwko LIV-1 i ich zastosowanie do leczenia nowotworu
PL11847198T PL2648752T3 (pl) 2010-12-06 2011-12-06 Humanizowane przeciwciała przeciwko liv-1 oraz ich zastosowanie do leczenia raka

Family Applications After (2)

Application Number Title Priority Date Filing Date
PL18204152T PL3461847T3 (pl) 2010-12-06 2011-12-06 Przeciwciała humanizowane przeciwko LIV-1 i ich zastosowanie do leczenia nowotworu
PL11847198T PL2648752T3 (pl) 2010-12-06 2011-12-06 Humanizowane przeciwciała przeciwko liv-1 oraz ich zastosowanie do leczenia raka

Country Status (25)

Country Link
US (6) USRE48959E1 (pl)
EP (4) EP3461847B1 (pl)
JP (5) JP6105481B2 (pl)
KR (5) KR20230057485A (pl)
CN (1) CN103533957B (pl)
AU (4) AU2011338480B8 (pl)
BR (2) BR122021020513B1 (pl)
CA (2) CA2819038C (pl)
CY (3) CY1118874T1 (pl)
DK (3) DK2648752T3 (pl)
ES (3) ES2842895T3 (pl)
HR (1) HRP20170567T1 (pl)
HU (3) HUE043355T2 (pl)
IL (4) IL299837A (pl)
LT (1) LT2648752T (pl)
MX (2) MX351027B (pl)
NZ (1) NZ611468A (pl)
PL (3) PL3156420T3 (pl)
PT (3) PT3156420T (pl)
RS (1) RS55843B1 (pl)
RU (1) RU2608646C2 (pl)
SG (3) SG190938A1 (pl)
SI (3) SI2648752T1 (pl)
WO (1) WO2012078688A2 (pl)
ZA (1) ZA201303803B (pl)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL3156420T3 (pl) 2010-12-06 2019-08-30 Seattle Genetics, Inc. Humanizowane przeciwciała przeciw liv-1 i ich stosowanie w leczeniu raka
JP6538561B2 (ja) 2012-10-25 2019-07-03 バイオベラティブ・ユーエスエイ・インコーポレイテッド 抗補体Ｃ１ｓ抗体とそれらの用途
GB2509260B (en) 2012-11-02 2016-05-04 True North Therapeutics Inc Anti-complement C1s antibodies and uses thereof
US9353150B2 (en) 2012-12-04 2016-05-31 Massachusetts Institute Of Technology Substituted pyrazino[1′,2′:1 ,5]pyrrolo[2,3-b]-indole-1,4-diones for cancer treatment
MX2015008448A (es) 2012-12-27 2016-04-07 Sanofi Sa Anticuerpos anti-lamp1 y conjugados anticuerpo farmaco, y usos de estos.
IL243690B (en) * 2013-07-31 2022-09-01 Amgen Inc Stabilization of polypeptides involving fc
SG10201806917PA (en) 2013-10-15 2018-09-27 Seattle Genetics Inc Pegylated drug-linkers for improved ligand-drug conjugate pharmacokinetics
IL309933A (en) 2014-02-17 2024-03-01 Seagen Inc Hydrophilic antibody-drug conjugates
PT3280440T (pt) 2015-04-06 2023-02-14 Bioverativ Usa Inc Anticorpos anti-c1s humanizados e métodos de utilização destes
US11793880B2 (en) 2015-12-04 2023-10-24 Seagen Inc. Conjugates of quaternized tubulysin compounds
TWI852735B (zh) 2015-12-04 2024-08-11 美商思進公司 四級胺化妥布賴森(tubulysin)化合物之結合物
CN116063503A (zh) * 2016-02-17 2023-05-05 思进股份有限公司 Bcma抗体和其用以治疗癌症和免疫病症的用途
MA45324A (fr) * 2016-03-15 2019-01-23 Seattle Genetics Inc Polythérapie utilisant un adc-liv1 et un agent chimiothérapeutique
WO2017165851A1 (en) 2016-03-25 2017-09-28 Seattle Genetics, Inc. Process for the preparation of pegylated drug-linkers and intermediates thereof
WO2017197045A1 (en) 2016-05-11 2017-11-16 Movassaghi Mohammad Convergent and enantioselective total synthesis of communesin analogs
TWI851531B (zh) 2016-08-09 2024-08-11 美商思進公司 具有改善之生理化學性質之具自我穩定連接子之藥物結合物
EA201891851A1 (ru) * 2016-09-16 2019-04-30 Сиэтл Дженетикс, Инк. Антитела против bcma и их применение для лечения злокачественных новообразований и иммунологических нарушений
KR20190074292A (ko) 2016-10-18 2019-06-27 시애틀 지네틱스, 인크. 니코틴아미드 아데닌 디뉴클레오티드의 구제 경로 저해제의 표적화된 전달
BR112019019116A2 (pt) 2017-03-15 2020-05-05 Silverback Therapeutics Inc compostos de benzazepina, conjugados, e usos dos mesmos
EP3600443A1 (en) 2017-03-24 2020-02-05 Seattle Genetics, Inc. Process for the preparation of glucuronide drug-linkers and intermediates thereof
WO2018191865A1 (en) 2017-04-18 2018-10-25 3M Innovative Properties Company Air filter media with post-pleat-deposited sorbent particles
US11931414B2 (en) 2017-04-27 2024-03-19 Seagen Inc. Quaternized nicotinamide adenine dinucleotide salvage pathway inhibitor conjugates
US11932650B2 (en) 2017-05-11 2024-03-19 Massachusetts Institute Of Technology Potent agelastatin derivatives as modulators for cancer invasion and metastasis
RU2020112280A (ru) * 2017-09-02 2021-10-05 Эббви Инк. Конъюгаты анти-egfr антитело-лекарственное средство (adc) и их применение
CA3073331A1 (en) * 2017-09-02 2019-03-07 Abbvie Inc. Anti-egfr antibody drug conjugates (adc) and uses thereof
US10640508B2 (en) 2017-10-13 2020-05-05 Massachusetts Institute Of Technology Diazene directed modular synthesis of compounds with quaternary carbon centers
SG11202004751TA (en) * 2017-12-01 2020-06-29 Seattle Genetics Inc Humanized anti-liv1 antibodies for the treatment of breast cancer
CN111989339A (zh) 2018-02-20 2020-11-24 西雅图基因公司 疏水性奥瑞他汀f化合物及其缀合物
CA3111784A1 (en) 2018-09-12 2020-03-19 Silverback Therapeutics, Inc. Methods and compositions for the treatment of disease with immune stimulatory conjugates
CA3111580A1 (en) 2018-09-12 2020-03-19 Silverback Therapeutics, Inc. Antibody conjugates of toll-like receptor agonists
WO2020056198A2 (en) 2018-09-12 2020-03-19 Silverback Therapeutics, Inc. Substituted benzazepine compounds, conjugates, and uses thereof
WO2020056194A1 (en) 2018-09-12 2020-03-19 Silverback Therapeutics, Inc. Benzazepine compounds, conjugates, and uses thereof
MX2021005395A (es) 2018-11-07 2021-09-14 Crispr Therapeutics Ag Terapia del cáncer con células inmunitarias anti-liv1.
US20220233709A1 (en) 2019-06-05 2022-07-28 Seagen Inc. Masked Antibody Formulations
TW202112801A (zh) 2019-06-05 2021-04-01 美商西雅圖遺傳學公司 純化遮蔽抗體之方法
WO2020247054A1 (en) 2019-06-05 2020-12-10 Massachusetts Institute Of Technology Compounds, conjugates, and compositions of epipolythiodiketopiperazines and polythiodiketopiperazines and uses thereof
CN114423464A (zh) * 2019-07-22 2022-04-29 西根股份有限公司 用于治疗癌症的人源化抗liv1抗体
JP2022544543A (ja) 2019-08-15 2022-10-19 シルバーバック セラピューティックス インコーポレイテッド ベンザゼピンコンジュゲートの製剤およびその使用
WO2021067644A1 (en) 2019-10-01 2021-04-08 Silverback Therapeutics, Inc. Combination therapy with immune stimulatory conjugates
TW202133887A (zh) 2019-12-09 2021-09-16 美商西健公司 使用liv1-adc及pd-1拮抗劑之組合療法
TW202138388A (zh) 2019-12-30 2021-10-16 美商西根公司 以非海藻糖苷化抗－ｃｄ７０抗體治療癌症之方法
EP4106819A1 (en) 2020-02-21 2022-12-28 Silverback Therapeutics, Inc. Nectin-4 antibody conjugates and uses thereof
WO2022006327A1 (en) 2020-07-01 2022-01-06 Silverback Therapeutics, Inc. Anti-asgr1 antibody conjugates and uses thereof
WO2022067348A1 (en) * 2020-09-28 2022-03-31 Seagen Inc. Humanized anti-liv1 antibodies for the treatment of cancer
AR124681A1 (es) 2021-01-20 2023-04-26 Abbvie Inc Conjugados anticuerpo-fármaco anti-egfr
WO2022182415A1 (en) 2021-02-24 2022-09-01 Massachusetts Institute Of Technology Himastatin derivatives, and processes of preparation thereof, and uses thereof
WO2022198231A1 (en) 2021-03-18 2022-09-22 Seagen Inc. Selective drug release from internalized conjugates of biologically active compounds
WO2023288236A1 (en) 2021-07-14 2023-01-19 Seagen Inc. Antibody masking domains
WO2023049825A1 (en) 2021-09-24 2023-03-30 Seagen Inc. Improved antibody masking domains
WO2023111913A1 (en) 2021-12-15 2023-06-22 Crispr Therapeutics Ag Engineered anti-liv1 cell with regnase-1 and/or tgfbrii disruption
WO2024109944A1 (zh) * 2022-11-25 2024-05-30 江苏恒瑞医药股份有限公司 抗liv-1抗体、其药物偶联物及其医药用途
WO2024165056A1 (en) * 2023-02-07 2024-08-15 LaNova Medicines Limited Antibodies targeting liv-1 and uses thereof
WO2024188339A1 (zh) * 2023-03-15 2024-09-19 浙江博锐生物制药有限公司 抗liv-1抗体和抗liv-1抗体药物偶联物及其药物用途

Family Cites Families (87)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH652145A5 (de) 1982-01-22 1985-10-31 Sandoz Ag Verfahren zur in vitro-herstellung von hybridomen welche humane monoklonale antikoerper erzeugen.
US4634666A (en) 1984-01-06 1987-01-06 The Board Of Trustees Of The Leland Stanford Junior University Human-murine hybridoma fusion partner
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4880935A (en) 1986-07-11 1989-11-14 Icrf (Patents) Limited Heterobifunctional linking agents derived from N-succinimido-dithio-alpha methyl-methylene-benzoates
WO1988007089A1 (en) 1987-03-18 1988-09-22 Medical Research Council Altered antibodies
IL106992A (en) 1988-02-11 1994-06-24 Bristol Myers Squibb Co Noble hydrazonic history of anthracycline and methods for their preparation
DE68921982D1 (de) 1988-06-14 1995-05-04 Cetus Oncology Corp Kupplungsmittel und sterisch gehinderte, mit disulfid gebundene konjugate daraus.
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
DK0463151T3 (da) 1990-01-12 1996-07-01 Cell Genesys Inc Frembringelse af xenogene antistoffer
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US5877397A (en) 1990-08-29 1999-03-02 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
DK0814159T3 (da) 1990-08-29 2005-10-24 Genpharm Int Transgene, ikke-humane dyr, der er i stand til at danne heterologe antistoffer
US5874299A (en) 1990-08-29 1999-02-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
WO1993012227A1 (en) 1991-12-17 1993-06-24 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5789650A (en) 1990-08-29 1998-08-04 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5858657A (en) 1992-05-15 1999-01-12 Medical Research Council Methods for producing members of specific binding pairs
US5871907A (en) 1991-05-15 1999-02-16 Medical Research Council Methods for producing members of specific binding pairs
EP0940468A1 (en) 1991-06-14 1999-09-08 Genentech, Inc. Humanized antibody variable domain
DE69228300T2 (de) 1991-08-22 1999-09-23 Becton Dickinson And Co., Franklin Lakes Methoden und zusammensetzungen zur krebstherapie und zur vorhersagbarkeit der reaktionen auf diese behandlung
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
US5622929A (en) 1992-01-23 1997-04-22 Bristol-Myers Squibb Company Thioether conjugates
US5733743A (en) 1992-03-24 1998-03-31 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
DK0672142T3 (da) 1992-12-04 2001-06-18 Medical Res Council Multivalente og multispecifikke bindingsproteiner samt fremstilling og anvendelse af disse
US6214345B1 (en) 1993-05-14 2001-04-10 Bristol-Myers Squibb Co. Lysosomal enzyme-cleavable antitumor drug conjugates
US5914349A (en) 1994-01-10 1999-06-22 Teva Pharmaceutical Industries, Ltd. Compositions containing and methods of using 1-aminoindan and derivatives thereof and process for preparing optically active 1-aminoindan derivatives
CA2132500A1 (en) 1994-09-20 1996-03-21 David Lockwood Manning Methods for predicting the behaviour of breast tumours
ATE234635T1 (de) 1995-12-22 2003-04-15 Bristol Myers Squibb Co Verzweigte hydrazongruppen enthaltende kuppler
US5834597A (en) 1996-05-20 1998-11-10 Protein Design Labs, Inc. Mutated nonactivating IgG2 domains and anti CD3 antibodies incorporating the same
US6130237A (en) 1996-09-12 2000-10-10 Cancer Research Campaign Technology Limited Condensed N-aclyindoles as antitumor agents
JP4614472B2 (ja) 1996-10-31 2011-01-19 アボット・ラボラトリーズ 乳房の疾患の検出に有用な試薬および方法
US6066778A (en) 1996-11-06 2000-05-23 The Regents Of The University Of Michigan Transgenic mice expressing APC resistant factor V
WO1998034118A1 (en) 1997-01-30 1998-08-06 Yale University Diagnostic methods and compositions based on the distribution of rad51
EP1027444A1 (en) 1997-10-31 2000-08-16 Abbott Laboratories Reagents and methods useful for detecting diseases of the breast
WO1999025877A1 (en) 1997-11-18 1999-05-27 Abbott Laboratories Reagents and methods useful for detecting diseases of the breast
AU2010699A (en) 1997-12-24 1999-07-19 Corixa Corporation Compounds for immunotherapy and diagnosis of breast cancer and methods for theiruse
EP1105528A4 (en) 1998-08-04 2002-09-04 Diadexus Inc NEW METHOD FOR DIAGNOSING, MONITORING BREAST CANCER, DETERMINING THE STAGE AND IMAGING AND TREATING IT
EP1953229A3 (en) 1998-10-15 2008-12-24 Novartis Vaccines and Diagnostics, Inc. Metastatic breast and colon cancer regulated genes
MY128897A (en) 1999-02-05 2007-02-28 Samsung Electronics Co Ltd Image texture retrieving method and apparatus thereof
AU3395900A (en) 1999-03-12 2000-10-04 Human Genome Sciences, Inc. Human lung cancer associated gene sequences and polypeptides
US6762020B1 (en) 1999-03-15 2004-07-13 Protein Design Labs, Inc. Methods of diagnosing breast cancer
US20040141983A1 (en) 1999-03-15 2004-07-22 Protein Design Labs, Inc. Compositions against cancer antigen LIV-1 and uses thereof
AU3458401A (en) 2000-01-25 2001-08-07 Genentech Inc. Compositions and methods for treatment of cancer
WO2001096372A2 (en) 2000-06-13 2001-12-20 University College Cardiff Consultants Ltd Zinc transporters proteins and their use in medicinal preparations
US6964849B2 (en) 2001-01-11 2005-11-15 Curagen Corporation Proteins and nucleic acids encoding same
US6884869B2 (en) 2001-04-30 2005-04-26 Seattle Genetics, Inc. Pentapeptide compounds and uses related thereto
WO2003004989A2 (en) 2001-06-21 2003-01-16 Millennium Pharmaceuticals, Inc. Compositions, kits, and methods for identification, assessment, prevention, and therapy of breast cancer
EP1410013A4 (en) 2001-06-21 2006-02-01 Millennium Pharm Inc COMPOSITIONS, NEEDS AND METHODS FOR THE IDENTIFICATION, EVALUATION, PREVENTION AND TREATMENT OF BREAST CANCERS AND OVARIA
EP1539233B1 (en) 2001-07-12 2011-04-27 FOOTE, Jefferson Super humanized antibodies
US7091186B2 (en) 2001-09-24 2006-08-15 Seattle Genetics, Inc. p-Amidobenzylethers in drug delivery agents
PT1572087E (pt) 2002-03-08 2008-07-11 Pdl Biopharma Inc Anticorpos contra o antigénio de cancro tmeff2 e suas utilizações
EP1545613B9 (en) 2002-07-31 2012-01-25 Seattle Genetics, Inc. Auristatin conjugates and their use for treating cancer, an autoimmune disease or an infectious disease
CN1849337A (zh) * 2003-01-27 2006-10-18 比奥根艾迪克Ma公司 利用igsf9和liv－1的、用于治疗癌症的组合物及方法
WO2004067564A2 (en) 2003-01-29 2004-08-12 Protein Design Labs, Inc. Compositions against cancer antigen liv-1 and uses thereof
KR20050010267A (ko) 2003-07-18 2005-01-27 삼성전자주식회사 식각장치
ES2605443T3 (es) 2003-11-06 2017-03-14 Seattle Genetics, Inc. Conjugados de auristatina con anticuerpos anti-HER2 o anti-CD22 y su uso en terapia
US7371381B2 (en) * 2003-12-12 2008-05-13 Amgen Inc. Anti-galanin antibodies and uses thereof
US7501121B2 (en) * 2004-06-17 2009-03-10 Wyeth IL-13 binding agents
KR20070040824A (ko) 2004-07-30 2007-04-17 리나트 뉴로사이언스 코퍼레이션 아밀로이드-베타 펩티드에 대해 지시된 항체 및 이의 사용방법
US20060222653A1 (en) * 2004-11-12 2006-10-05 Xencor, Inc. Antibodies operably linked to selected chemoattractants
WO2006124269A2 (en) 2005-05-16 2006-11-23 Amgen Fremont Inc. Human monoclonal antibodies that bind to very late antigen-1 for the treatment of inflammation and other disorders
KR20080080482A (ko) 2005-09-07 2008-09-04 메디뮨 엘엘씨 독소가 컨쥬게이트된 ｅｐｈ 수용체 항체
BRPI0710616A2 (pt) 2006-04-13 2011-08-16 Novartis Vaccines & Diagnostic métodos para tratar, diagnosticar ou detectar cáncer
WO2008070593A2 (en) 2006-12-01 2008-06-12 Seattle Genetics, Inc. Variant target binding agents and uses thereof
JP2010527916A (ja) * 2007-04-23 2010-08-19 ワイス・エルエルシー Ｉｌ−１３関連障害を治療する方法および組成物ならびにその治療をモニターする方法
AU2008328726B2 (en) * 2007-11-30 2014-06-12 Glaxo Group Limited Antigen-binding constructs
WO2009135181A2 (en) 2008-05-02 2009-11-05 Seattle Genetics, Inc. Methods and compositions for making antibodies and antibody derivatives with reduced core fucosylation
US20110166838A1 (en) 2008-06-16 2011-07-07 Sividon Diagnostics Algorithms for outcome prediction in patients with node-positive chemotherapy-treated breast cancer
US20110195995A1 (en) 2008-10-14 2011-08-11 Wittliff James L Methods of Optimizing Treatment of Estrogen-Receptor Positive Breast Cancers
WO2010069858A1 (en) 2008-12-19 2010-06-24 F. Hoffmann-La Roche Ag Pharmaceutical composition
US8642270B2 (en) 2009-02-09 2014-02-04 Vm Institute Of Research Prognostic biomarkers to predict overall survival and metastatic disease in patients with triple negative breast cancer
US20110165566A1 (en) 2009-07-09 2011-07-07 Wittliff James L Methods of optimizing treatment of breast cancer
US8728730B2 (en) 2009-09-03 2014-05-20 Genentech, Inc. Methods for treating, diagnosing, and monitoring rheumatoid arthritis
PL3156420T3 (pl) 2010-12-06 2019-08-30 Seattle Genetics, Inc. Humanizowane przeciwciała przeciw liv-1 i ich stosowanie w leczeniu raka
WO2012125712A2 (en) 2011-03-14 2012-09-20 Respira Health, Llc Lung tumor classifier for current and former smokers
KR101645905B1 (ko) 2012-10-12 2016-08-04 스피로즌 살 피롤로벤조디아제핀 및 그의 컨주게이트
MA45324A (fr) 2016-03-15 2019-01-23 Seattle Genetics Inc Polythérapie utilisant un adc-liv1 et un agent chimiothérapeutique
SG11202004751TA (en) 2017-12-01 2020-06-29 Seattle Genetics Inc Humanized anti-liv1 antibodies for the treatment of breast cancer
MX2021005395A (es) 2018-11-07 2021-09-14 Crispr Therapeutics Ag Terapia del cáncer con células inmunitarias anti-liv1.
GB201908208D0 (en) 2019-06-10 2019-07-24 Univ College Cardiff Consultants Ltd An anti-mitotic agent

Also Published As

Publication number Publication date
US9228026B2 (en) 2016-01-05
SI2648752T1 (sl) 2017-06-30
IL299837A (en) 2023-03-01
JP2021106599A (ja) 2021-07-29
JP2019073515A (ja) 2019-05-16
PT2648752T (pt) 2017-03-28
CA2819038C (en) 2023-10-17
JP6869218B2 (ja) 2021-05-12
EP2648752B1 (en) 2017-02-15
HRP20170567T1 (hr) 2017-06-16
KR102198189B1 (ko) 2021-01-05
PL2648752T3 (pl) 2017-07-31
AU2011338480A8 (en) 2017-03-23
LT2648752T (lt) 2017-04-10
AU2011338480B8 (en) 2017-03-23
JP7166384B2 (ja) 2022-11-07
MX2013006365A (es) 2013-08-15
JP6453924B2 (ja) 2019-01-16
PT3461847T (pt) 2020-12-24
AU2017203851A1 (en) 2017-06-22
IL273607B2 (en) 2023-06-01
BR112013013781A2 (pt) 2016-09-13
WO2012078688A2 (en) 2012-06-14
JP2017149717A (ja) 2017-08-31
SI3156420T1 (sl) 2019-05-31
US20180079810A1 (en) 2018-03-22
US20130259860A1 (en) 2013-10-03
CA3211246A1 (en) 2012-06-14
HUE043355T2 (hu) 2019-08-28
ES2842895T3 (es) 2021-07-15
AU2019202530A1 (en) 2019-05-02
MX351027B (es) 2017-09-28
IL226754B (en) 2018-10-31
AU2019202530B2 (en) 2021-04-01
KR20200145867A (ko) 2020-12-30
SI3461847T1 (sl) 2021-03-31
EP2648752A4 (en) 2015-05-20
US20200165335A1 (en) 2020-05-28
BR122021020513B1 (pt) 2022-10-25
IL273607A (en) 2020-05-31
SG10201510041QA (en) 2016-01-28
PL3461847T3 (pl) 2021-07-05
EP3461847B1 (en) 2020-09-23
EP3461847A8 (en) 2021-04-14
CY1121546T1 (el) 2020-05-29
NZ611468A (en) 2015-06-26
IL261900A (en) 2018-10-31
CN103533957B (zh) 2016-06-22
EP3156420B1 (en) 2019-02-20
EP3461847A1 (en) 2019-04-03
HUE052806T2 (hu) 2021-05-28
WO2012078688A3 (en) 2012-08-23
KR20190076068A (ko) 2019-07-01
KR20230057485A (ko) 2023-04-28
KR20130135884A (ko) 2013-12-11
CY1123883T1 (el) 2022-03-24
ES2719548T3 (es) 2019-07-11
CA2819038A1 (en) 2012-06-14
CN103533957A (zh) 2014-01-22
USRE48959E1 (en) 2022-03-08
AU2021204473B2 (en) 2024-07-18
MX2020010639A (es) 2020-10-28
JP2023011709A (ja) 2023-01-24
US9783608B2 (en) 2017-10-10
KR101993921B1 (ko) 2019-06-28
EP3156420A1 (en) 2017-04-19
ZA201303803B (en) 2014-07-30
DK3461847T3 (da) 2020-12-14
ES2620264T3 (es) 2017-06-28
DK3156420T3 (en) 2019-04-29
CY1118874T1 (el) 2018-01-10
RU2608646C2 (ru) 2017-01-23
AU2011338480A1 (en) 2013-06-13
EP2648752A2 (en) 2013-10-16
SG190938A1 (en) 2013-07-31
EP3786185A1 (en) 2021-03-03
US20240247059A1 (en) 2024-07-25
JP2014506120A (ja) 2014-03-13
RU2013130609A (ru) 2015-01-20
JP6105481B2 (ja) 2017-03-29
RS55843B1 (sr) 2017-08-31
SG10201912646UA (en) 2020-02-27
US20160185858A1 (en) 2016-06-30
HUE031726T2 (en) 2017-07-28
KR20220011811A (ko) 2022-01-28
AU2021204473A1 (en) 2021-07-29
DK2648752T3 (en) 2017-03-27
AU2017203851B2 (en) 2019-01-31
AU2011338480B2 (en) 2017-03-16
PT3156420T (pt) 2019-05-27

Similar Documents

Publication Publication Date Title
ZA201303803B (en) Humanized antibodies to liv-1 and use of same to treat cancer
HUS1900007I1 (hu) Kiméra, antigénreceptor-módosított T-sejt alkalmazása rák kezelésére
IL237960B (en) Combination of anti-kir antibodies and anti-pd-1 antibodies for cancer treatment
EP2604626A4 (en) FRAGMENT OF A HUMANIZED ANTI-EGFR ANTIBODY, VARIABLE FRAGMENT OF SUBSTITUTED LYSINE AND USE THEREOF
EP2700652A4 (en) DIAGNOSIS AND TREATMENT OF CANCER BY ANTI-ITM2A ANTIBODIES
HK1201855A1 (en) Antibodies and methods of treating cancer
PL2550296T3 (pl) Przeciwciała monoklonalne w leczeniu nowotworów
EP2575882A4 (en) HUMANIZED MONOCLONAL ANTIBODIES AND METHODS OF USE